View More Recent Stories

Dec 21, 2020 08:30AM DURECT Corporation to Participate in Investor Conferences in January 2021
Dec 16, 2020 08:36AM DURECT Corp (DRRX) Announces DUR-928 Granted FDA Fast Track Designation for Treatment of Alcoholic Hepatitis
Dec 16, 2020 08:30AM DURECT Corporation Announces DUR-928 Granted FDA Fast Track Designation for Treatment of Alcoholic Hepatitis
Dec 7, 2020 11:16AM DURECT Corp (DRRX) to Sell its LACTEL Absorbable Polymer Product Line to Evonik for $15 Million
Dec 7, 2020 11:15AM DURECT Corporation to Sell its LACTEL® Absorbable Polymer Product Line to Evonik for $15 Million
Nov 13, 2020 09:01AM DURECT Corp (DRRX) Reports Additional Safety Data & Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients
Nov 13, 2020 09:00AM DURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020
Nov 10, 2020 08:30AM DURECT Corporation to Host Webinar on the Treatment of Alcoholic Hepatitis Featuring Chief Medical Officer Dr. Norman Sussman
Nov 2, 2020 04:02PM DURECT Corporation Appoints Dr. Norman Sussman as Chief Medical Officer
Oct 27, 2020 08:30AM DURECT Corporation to Announce Third Quarter 2020 Financial Results and Provide Business Update on November 02, 2020
Oct 26, 2020 04:30PM DURECT Corporation to Participate in the ROTH Capital Partners Healthcare Event "Covid-19 Therapeutics in Development"
Oct 21, 2020 07:00AM AVROBIO Appoints Dr. Gail Farfel to its Board of Directors
Oct 5, 2020 08:34AM DURECT Corp (DRRX) to Present Additional Safety and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting
Oct 5, 2020 08:30AM DURECT Corporation to Present Additional Safety and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020
Sep 30, 2020 04:53PM DURECT Corporation to Participate in Fireside Chat at H.C. Wainwright 4th Annual NASH Investor Conference
Sep 23, 2020 08:32AM DURECT Corp (DRRX) Reports First Patient Dosed in Phase 2 Safety and Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury
Sep 23, 2020 08:30AM DURECT Corporation Announces First Patient Dosed in Phase 2 Safety and Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury
Sep 22, 2020 08:33AM DURECT Corp (DRRX) Announces Design of Phase 2b AH Study (AHFIRM)
Sep 22, 2020 08:30AM DURECT Corporation Announces Design of Phase 2b AH Study (AHFIRM)
Sep 10, 2020 08:30AM DURECT Corporation to Participate in September Virtual Investor Conferences
Aug 27, 2020 08:36AM DURECT Corp (DRRX) Highlights Phase 2a Pharmacokinetic Data of DUR-928 in Alcoholic Hepatitis at EASL 2020 Meetings
Aug 27, 2020 08:30AM DURECT Corporation Announces Presentation of Phase 2a Pharmacokinetic Data of DUR-928 in Alcoholic Hepatitis at Digital International Liver Congress (EASL)
Aug 26, 2020 04:30PM DURECT Corporation Fireside Chat hosted by Ellie Merle of Cantor Fitzgerald
Sep 26, 2016 09:29AM Pre-Open Stock Movers 09/26: (ARRY) (CHMT) (GWPH) Higher; (PTIE) (DRRX) (SALE) Lower (more...)
Oct 27, 2014 05:30PM Market Wrap: Valeant Lifts Allergan Bid; Twitter's Ho-Hum Q3 Report; Tesla Slumps on Sales Speculation
Nov 1, 2012 11:13AM UPDATE: Pain Therapeutics (PTIE), DURECT (DRRX) Sink in Active Trade
View More Recent Stories